Anaphylaxis is a severe, generalized allergic or hypersensitivity reaction that is rapid in onset and may cause death. Epinephrine (adrenaline) can be life-saving when administered as rapidly as possible once anaphylaxis is recognized. This clinical report from the American Academy of Pediatrics is an update of the 2007 clinical report on this topic. It provides information to help clinicians identify patients at risk of anaphylaxis and new information about epinephrine and epinephrine autoinjectors (EAs). The report also highlights the importance of patient and family education about the recognition and management of anaphylaxis in the community. Key points emphasized include the following: (1) validated clinical criteria are available to facilitate prompt diagnosis of anaphylaxis; (2) prompt intramuscular epinephrine injection in the mid-outer thigh reduces hospitalizations, morbidity, and mortality; (3) prescribing EAs facilitates timely epinephrine injection in community settings for patients with a history of anaphylaxis and, if specifi c circumstances warrant, for some high-risk patients who have not previously experienced anaphylaxis; (4) prescribing epinephrine for infants and young children weighing <15 kg, especially those who weigh 7.5 kg and under, currently presents a dilemma, because the lowest dose available in EAs, 0.15 mg, is a high dose for many infants and some young children; (5) effective management of anaphylaxis in the community requires a comprehensive approach involving children, families, preschools, schools, camps, and sports organizations; and (6) prevention of anaphylaxis recurrences involves confi rmation of the trigger, discussion of specifi c allergen avoidance, allergen immunotherapy (eg, with stinging insect venom, if relevant), and a written, personalized anaphylaxis emergency action plan; and (7) the management of anaphylaxis also involves education of children and supervising adults about anaphylaxis recognition and fi rst-aid treatment.
abstract
Anaphylaxis is a severe, generalized allergic or hypersensitivity reaction that is rapid in onset and may cause death. Epinephrine (adrenaline) can be life-saving when administered as rapidly as possible once anaphylaxis is recognized. This clinical report from the American Academy of Pediatrics is an update of the 2007 clinical report on this topic. It provides information to help clinicians identify patients at risk of anaphylaxis and new information about epinephrine and epinephrine autoinjectors (EAs). The report also highlights the importance of patient and family education about the recognition and management of anaphylaxis in the community. Key points emphasized include the following: (1) validated clinical criteria are available to facilitate prompt diagnosis of anaphylaxis; (2) prompt intramuscular epinephrine injection in the mid-outer thigh reduces hospitalizations, morbidity, and mortality; (3) prescribing EAs facilitates timely epinephrine injection in community settings for patients with a history of anaphylaxis and, if specifi c circumstances warrant, for some high-risk patients who have not previously experienced anaphylaxis; (4) prescribing epinephrine for infants and young children weighing <15 kg, especially those who weigh 7.5 kg and under, currently presents a dilemma, because the lowest dose available in EAs, 0.15 mg, is a high dose for many infants and some young children; (5) effective management of anaphylaxis in the community requires a comprehensive approach involving children, families, preschools, schools, camps, and sports organizations; and (6) prevention of anaphylaxis recurrences involves confi rmation of the trigger, discussion of specifi c allergen avoidance, allergen immunotherapy (eg, with stinging insect venom, if relevant), and a written, personalized anaphylaxis emergency action plan; and (7) the management of anaphylaxis also involves education of children and supervising adults about anaphylaxis recognition and fi rst-aid treatment.
INTRODUCTION
Anaphylaxis is defined as a serious, generalized allergic or hypersensitivity reaction that is rapid in onset and potentially fatal.
Clinical presentation and severity can vary among patients and in the same patient from 1 anaphylactic episode to another. 1 -3 Epinephrine is the primary initial treatment of anaphylaxis. [1] [2] [3] This clinical report from the American Academy of Pediatrics (AAP) updates and amplifies the previous report on this topic. 4 
CLINICAL FEATURES OF ANAPHYLAXIS
Clinical criteria for anaphylaxis have been proposed and validated. 3, 5 Anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled: 
PRIMARY ROLE OF EPINEPHRINE
Epinephrine is the medication of choice for the first-aid treatment of anaphylaxis. Through vasoconstrictor effects, it prevents or decreases upper airway mucosal edema (laryngeal edema), hypotension, and shock. In addition, it has important bronchodilator effects and cardiac inotropic and chronotropic effects. 1 -4, 19 -24 Delayed epinephrine administration in anaphylaxis is associated with an increased risk of hospitalization 22 and poor outcomes, including hypoxic-ischemic encephalopathy and death. 16 -18 Conversely, prompt prehospital epinephrine injection is associated with a lower risk of hospitalization 22 and fatality. 
EPINEPHRINE ADMINISTRATION AND DOSING
Epinephrine can be life-saving when injected promptly by the intramuscular (IM) route in the midouter thigh (vastus lateralis muscle) as soon as anaphylaxis is recognized ( Table 1) Subsequent epinephrine doses are needed for severe or rapidly progressive anaphylaxis and for failure to respond to the initial injection because of delayed injection of the initial dose, inadequate initial dose, or administration through a suboptimal route. 23 Subsequent doses also might be needed in biphasic anaphylaxis, defined as recurrence of symptoms hours after resolution of initial symptoms despite no further exposure to the trigger, which is reported in up to 11% of pediatric patients. Foodinduced anaphylaxis is associated with biphasic anaphylaxis less often than is venom-or drug-induced anaphylaxis. 32, 33 Reluctance to inject epinephrine promptly at the onset of anaphylaxis symptoms is best overcome by awareness that the severity of an anaphylactic episode can differ from 1 patient to another and in the same patient from 1 episode to another. 21 At the onset, it is impossible to predict whether the patient will respond promptly to treatment, die within minutes, or recover spontaneously because of secretion of endogenous epinephrine.
SAFETY OF EPINEPHRINE
Pharmacologic effects of epinephrine include transient pallor, tremor, anxiety, and palpitations, which, although perceived as adverse effects, are similar to the symptoms caused by increased endogenous epinephrine levels produced in the "fight or flight" response. These effects cannot be dissociated from the beneficial effects of epinephrine. 23 Epinephrine given by IM injection achieves peak concentrations faster than that given by subcutaneous injection. 20 Epinephrine, 0.3 mg IM, is 10 times safer than epinephrine given as an intravenous bolus. 34 Serious adverse effects of IM epinephrine are rare in children.
There is no absolute contraindication to epinephrine treatment in anaphylaxis. 1 Adapted from refs 1 -3, 6 . can differ among patients, and even in the same patient from 1 episode to the next. Typically, more than 1 body organ system is involved. a Note that only a few anaphylaxis symptoms may be present during an episode. Also, symptoms a 1-mL ampule by using a 1-mL syringe. However, dose preparation can take laypersons as long as 3 to 4 minutes; moreover, doses typically are inaccurate and can sometimes contain no epinephrine at all when the solution is ejected from the syringe along with the air. 36 Although unsealed 1-mL syringes prefilled by a health care professional with infant epinephrine doses also have been recommended, the doses can be lost, and the epinephrine solution typically degrades within a few months as a result of air exposure. 37 After consideration of the aforementioned alternatives that potentially lead to delay in dosing, incorrect dosing, or no dose at all and consideration of the favorable benefit-to-risk ratio of epinephrine in young patients with anaphylaxis, many physicians recommend the use of the 0.15-mg EA in infants. 6 Most pediatricians (80%) report that they would prescribe the 0.15-mg EA for an infant or a child weighing 10 kg (22 lb). 38 International guidelines suggest that, when using EAs, patients weighing 7.5 to 25 kg should receive the 0.15-mg dose. 39 Physicians can discuss the benefits and risks of these options with families and prescribe on a case-bycase basis. 21 On the basis of a pharmacokinetic study 40 and expert consensus, it is appropriate to switch most children from the 0.15-mg dose to the 0.3-mg dose when they reach a body weight of 25 to 30 kg (55-66 lb). 4, 8, 35 
PRESCRIBING EAS
Most anaphylaxis deaths occur in community settings rather than in health care settings 1, 16 -18 ; yet, some physicians fail to prescribe EAs for their patients at risk of anaphylaxis in the community. 41 EA prescriptions also can be considered for patients with known sensitization to peanut, tree nuts, cow's milk, crustacean shellfish, and fish, which potentially are associated with severe and fatal anaphylaxis and can be difficult to avoid (eg, when peanut or milk are hidden ingredients in manufactured foods). 8, 9 Consideration of prescribing an EA is especially important if the patient has had a previous food-induced allergic reaction, such as generalized acute urticaria, has reacted to trace amounts of a food, or has food allergy and concomitant asthma, which increases the risk of fatality from anaphylaxis. In fact, some experts have suggested that consideration be given to prescribing EAs for all patients with immunoglobulin Emediated food allergy, because it is difficult or impossible to predict the occurrence or severity of future reactions. 8, 9 It can be beneficial to prescribe EAs for children with a history of acute generalized urticaria after an insect sting, because if re-stung, the risk of a more severe systemic reaction is approximately 5% in this population. 10, 35 Definitive evaluation by an allergy/ immunology specialist can provide confirmation of the diagnosis of anaphylaxis and the trigger and, for patients with idiopathic anaphylaxis, can clarify the diagnosis by performing additional investigations that reveal a trigger or identify comorbidities, such as systemic mastocytosis. 
USING EAS
Guidelines recommend prompt epinephrine injection for the sudden onset of any anaphylaxis symptoms after exposure to an allergen that previously caused anaphylaxis in that patient. 1, 2, 8 -10 Systemic allergic reactions can rapidly progress from mild to life-threatening symptoms, and early treatment before, or at the first sign of, symptoms can sometimes prevent escalation of symptoms. 35 As an example, generalized acute urticaria is not life-threatening; yet, in a community setting, in the context of a known exposure to an allergen (eg, peanut or milk) that previously triggered anaphylaxis, it could be beneficial to inject epinephrine to prevent additional symptoms. 8, 35 It can sometimes be difficult to distinguish anaphylaxis from other diagnostic entities such as acute asthma, acute generalized urticaria, aspiration of a foreign body such as a peanut, a vasovagal episode, or an anxiety or panic attack. 35 In such situations, if unsure, erring on the side of caution and injecting epinephrine, then observing the patient closely, is advised.
Even physicians with years of experience in diagnosing and treating anaphylaxis cannot determine, at the onset of an episode, whether that episode will remain mild or escalate over minutes to become life-threatening. In this situation, although some oral H 1 -antihistamines relieve itching and hives within 30 or 40 minutes, 25, 26 severe, life-threatening respiratory and/or cardiovascular symptoms can appear suddenly after the hives have disappeared. 1, 8, 24 In community settings, patients experiencing anaphylaxis or caregivers without medical training may be so anxious that they cannot assess the situation accurately and remember what to do. It is therefore important that physicians instruct patients and caregivers to err on the side of prompt epinephrine injection. 1, 3, 8, 35 Many patients and caregivers fail to carry EAs consistently or to use them when anaphylaxis occurs, even for severe symptoms, including throat tightness, difficulty breathing, wheezing, and loss of consciousness. 41, 45, 46 People may have different reasons for not using EAs, including failure to recognize anaphylaxis symptoms, spontaneous recovery from a previous anaphylactic episode and the assumption that this will happen in every episode, reliance on oral H 1 -antihistamines and/ or inhaled bronchodilators, no EA available, fear of needles, and concerns about epinephrine adverse effects. 41, 45 -48 Many parents fear using an EA because they worry about hurting or injuring their child or a bad outcome. 46, 47 Unintentional injections into digits and other body parts, with or without injuries, 48 and lacerations incurred when an inadequately restrained child moves during the injection are reported from pen-type EAs. 49 Teenagers are at increased risk of death in anaphylaxis 16 -18 because of high-risk behaviors, including ethanol and/or recreational drug use, failure to recognize triggers, denial of symptoms, and failure to carry their EAs and inject epinephrine promptly when anaphylaxis occurs. [16] [17] [18] Additional efforts to provide anaphylaxis education for adolescents, their peers, and their communities are needed. 50 Patients and caregivers need training in how to recognize anaphylaxis and use an EA.
Epinephrine injections can be given through clothing, although care must be taken to avoid obstructing seams or items in pockets. Regular review (eg, annually) of anaphylaxis recognition and injection technique is advisable, because errors are common and acquired skills may not be retained permanently. 51, 52 Technique can be practiced at home by using a "trainer." Various EAs may come to market having different mechanisms of activation and variations in ease of use. 53, 54 Education about anaphylaxis recognition and injection technique is advised to ensure familiarity with the specific device prescribed.
After treatment with epinephrine for anaphylaxis in community settings, it is important for patients to be assessed in an emergency department to determine whether additional interventions are needed. 1, 2, 8 It may be helpful for families to know they are seeking additional medical care not because of the use of the EA, a safe treatment, but rather to assess and monitor the anaphylactic episode.
Pediatric allergists who are members of the AAP Section on Allergy and Immunology were surveyed about when they typically begin to transfer responsibilities for anaphylaxis recognition and EA use from adult caregivers to children and teenagers at risk of anaphylaxis in community settings. They expected that by age 12 to 14 years, their patients should begin to share these responsibilities. They started to train early and individualized the time of transfer on the basis of patient factors, such as the presence of asthma and absence of cognitive dysfunction. 55 In contrast, caregivers of at-risk children and teenagers who were surveyed expected to begin transfer of responsibilities considerably earlier, by 6 to 11 years of age. 56 In both of these studies, the investigators commented that 6. Children who have experienced anaphylaxis benefit from evaluation by an allergy/ immunology specialist for confirmation of the diagnosis, confirmation of specific triggers, and preventive care.
